Lonza

@LonzaGroup

We are here to make . What we do today is helping to create a healthier, happier world tomorrow.

Basel, Switzerland
Vrijeme pridruživanja: srpanj 2009.

Tweetovi

Blokirali ste korisnika/cu @LonzaGroup

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LonzaGroup

  1. prije 12 sati

    How can we target tumours more precisely? By using antibody-drug conjugates. This treatment uses to deliver a highly potent drug into the cancer cell.

    Poništi
  2. 4. velj

    To acknowledge , we prepared an infographic of available by type. Learn more about treatments such as therapy, , , and more.

    Poništi
  3. 3. velj

    Lonza among top ten employers in Switzerland! One of the largest job portals in Switzerland, , recently published an annual evaluation of search queries. This year, Lonza made it into the top ten for the first time

    Poništi
  4. 31. sij

    that has two locations in Basel? Apart from the HQ in the well-known "Lonza Tower", we are also based in the Stücki Park. The building hosts several office floors and laboratories in our facility.

    Poništi
  5. 28. sij

    We're looking forward to working together with HES-SO Valais-Wallis to develop shared competencies in education and research!

    Poništi
  6. 23. sij

    Our CEO a.i. Albert M. Baehny enjoyed conversations about the recent progress of drug product manufacturing at our Lonza Stücki site in Basel. – mjesto: Lonza Drug Product Services

    Poništi
  7. 22. sij

    "Facilitating Cell Culture Growth and Protecting Protein Integrity", interview with 's Nicole Wellens, Global Product Manager for BioTherapeutics Media

    Poništi
  8. proslijedio/la je Tweet
    22. sij

    ’s Charles Christy discusses what lies ahead for in 2020, including single-use systems for mammalian manufacturing and hybrid processes for faster biologics manufacturing in :

    Poništi
  9. 21. sij

    Key message from Albert Baehny, Chairman and CEO ad interim, on our results:

    Poništi
  10. 21. sij

    The carve-out of Lonza's Specialty Ingredients segment is progressing in line with plans; completion is currently expected in mid-2020.

    Poništi
  11. 21. sij

    Lonza outlook 2020: above mid-single digit sales growth, mid-term guidance 2022 confirmed, supported by solid building blocks

    Poništi
  12. 21. sij

    Specialty Ingredients (LSI) shows improved 17.8% CORE EBITDA margin, despite sales growth of -3.2%; carve-out progressing according to plan

    Poništi
  13. 21. sij
    Poništi
  14. 21. sij

    Pharma Biotech & Nutrition (LPBN) as driver, with 11.0% sales growth and 32.9% CORE EBITDA margin

    Poništi
  15. 21. sij

    Lonza delivers on guidance with 6.8% sales growth, CHF 5.9bn sales, and CHF 1.6bn CORE EBITDA, resulting in a 27.4% margin

    Poništi
  16. 21. sij

    delivers strong full-year 2019 group results, with 11% pharma segment growth

    Poništi
  17. proslijedio/la je Tweet
    16. sij

    There are three parameters to consider when choosing the right capsule size. Need help finding which one is best for your application? Contact us.

    Poništi
  18. proslijedio/la je Tweet
    16. sij

    For the first time, are opening their doors for a open evening! Meet the team, take a tour of their Manchester Shared Services offices and make connections over food and drinks. Find out more & register here:

    Poništi
  19. 15. sij

    We’re starting 2020 on the right pedal stroke! Today, recognized Lonza with a Bronze Award for our efforts to build a bike bike-friendly workplace for our employees. Congrats to our team in Portsmouth and keep on cycling!

    Poništi
  20. proslijedio/la je Tweet
    15. sij

    Time to market for half that of other Tx (~3.5yrs) so vital to get dev right first time: Alberto Santagostino.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·